🎧 New on Citeline’s Pharma Intelligence: CEO Alan Watt & Lucie Ellis-Taitt explore our cutting-edge #NLRP3 inhibitors’ potential in fighting #inflammation, #obesity, and neurodegenerative diseases. To listen: podcasts.apple.com/us/podcast/nod…

Today we report positive Phase Ib/IIa results for our brain-penetrant #NLRP3 inhibitor NT-0796 in #Parkinson’s disease. Reductions in pro-inflammatory and #neurodegenerative biomarkers signal its potential to change the treatment paradigm. Learn more at bit.ly/3PcPchw

Following the #publication of our #obesity research last month, NodThera features in a new piece in BioCentury, which explores the potential of #NLRP3 inhibitors to enhance CV benefits. For more: biocentury.com/article/651740… #ICYMI #Pharma

This #ParkinsonsAwarenessMonth, we at NodThera are dedicated to pioneering treatments for neuroinflammatory conditions. Our work on #NLRP3 #inflammasome activity is aimed at not just easing symptoms but targeting disease roots. Let's raise awareness and hope for breakthroughs.

Exciting news from NodThera! Our study on #NLRP3 #Inflammasome Inhibitors NT-0249 & NT-0796 has been chosen as Editor's Choice & tops the most read in @JPET! This recognition fuels our journey to combat inflammation-related diseases. Thanks to our team & peers for the support!

We are pleased to share NodThera’s latest research publication detailing the preclinical pharmacology of our clinical-stage drug candidate, NT-0249, establishing its potency and selectivity as an #NLRP3 inhibitor: pubs.acs.org/doi/10.1021/ac…

We are pleased to welcome Dan Swisher as CEO! Dan brings more than 30 years of leadership experience in the #LifeSciences industry, where he led the advancement and commercialization of novel therapeutics. For more: [link to press release when live] #Appointment #NewHire #NLRP3

Today we reached another exciting clinical milestone, announcing positive data from a Phase Ib/IIa #cardiovascular (CV) risk study of lead #NLRP3 #inflammasone inhibitor candidate, NT-0796. For more: nodthera.com/news/nodtheras… #Neuroinflammation #DrugDiscovery #obesity

Tomorrow, our CSO, Alan Watt, will speak at the Future of Healthcare Investment Forum 2024 organized by London Stock Exchange. He will join an expert panel on Metabolic Diseases to share insights from our pioneering research. Follow this link to register: lnkd.in/dGbknNHf

In a recent conversations with @BioSpace, Alan Watt, our CSO, highlights NodThera’s innovative #NLRP3 #inflammasome inhibitor approach to addressing chronic #inflammation, marking a potential game-changer in Parkinson’s treatment. For more: biospace.com/drug-developme… #Biotech

We are pleased to share NodThera’s latest research publication detailing preclinical pharmacology of our clinical-stage drug candidate, NT-0796, describing its metabolism, potency and selectivity as an #NLRP3 inhibitor: doi.org/10.1016/j.bcp.…

Please join us in extending a warm welcome to Greg Chow, NodThera’s new Chief Financial and Business Officer! He joins the team with over 25 years of public and private leadership experience. Find out more here: nodthera.com/news/nodthera-… #Appointment #NewHire

We are delighted to have been named by FierceBiotech as one of its ‘Fierce 15’ in their 2024 report. See the full list of this year’s winners here: fiercebiotech.com/special-report… #NodThera #Fierce15 #NLRP3 #Innovation

Spotted on the trading floor at the NYSE 🏛 ! Great to see NodThera on the screens at the New York Stock Exchange following our inclusion in FierceBiotech ‘Fierce 15’ 2024 special report. #NodThera #Fierce15 #Innovation #NYSE #Biotech #NLRP3

#Inflammation is central to many diseases, from heart disease to dementia, as highlighted in the latest The New York Times article. At NodThera, we’re developing #NLRP3 targeting therapeutics to manage chronic inflammation without compromising the body's defenses. nytimes.com/2024/09/16/opi…

Delighted to have picked up our Fierce 15 award at the FierceBiotech Summit in Boston! Congratulations to all those involved in the event, and to all the other award winners! #NodThera #Fierce15 #Award #Innovation #Biotech #NLRP3

Thrilled to share that NodThera’s management will meet with investors at the 2024 Leerink Partners Biopharma Private Company Connect (Oct 22-23). Excited to discuss our progress in tackling chronic inflammation with NLRP3 inhibition! #Networking #NodThera #NLRP3

On Monday, Nodthera will be on the ground in London to discuss our #NLRP3 #inflammasome inhibitor approach to targeting diseases caused by chronic #inflammation with #investors at the LifeSci Capital and Sofinnova Partners Growth & Innovation Summit. #Biotech #Networking #Innovation

NodThera has been featured in a new In Vivo, Citeline Commercial article, which highlights the game-changing potential of #NLRP3 #inflammasome inhibitors in in anti-inflammatory treatment. For more: insights.citeline.com/in-vivo/market… #Inflammation #Innovation

Excited to attend the Piper Sandler 36th Annual Healthcare Conference, held from 3-5 Dec in NYC! We’ll share how #NodThera’s #NLRP3 inflammasome inhibitors are transforming #cardiometabolic & #neurodegenerative disease treatment. Let’s connect! #Networking #Inflammation